Unfit people even have the choice of venetoclax plus obinutuzumab (VO) as frontline therapy. This relies on the stage III trial that in comparison VO with ClbO in aged/unfit people.113 VO was outstanding with regards to reaction price and progression-no cost survival, and had a similar security profile. Within this https://elbertb975ucl2.blogpixi.com/profile